Centre Bans High-Dose Nimesulide Oral Drugs Above 100 mg

In a major regulatory decision, the Union Health Ministry has banned all oral formulations of Nimesulide exceeding 100 mg. The notification was issued on December 31, 2025, citing potential risks to human health and the availability of safer alternative medicines.

The move reflects India’s growing focus on pharmaceutical safety and patient protection.

Also Read

Centre Bans High-Dose Nimesulide Oral Drugs Above 100 mg

Health Ministry Notification and Rationale

According to the official notification, higher-dose oral formulations of Nimesulide pose a likely risk to public health, mainly due to concerns related to liver toxicity. Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) widely used to reduce fever and pain.

The decision was taken after consultations with the Drugs Technical Advisory Board, the apex technical advisory body on drug safety in India.

Notably:

• Nimesulide is already banned for children below 12 years
• It is also prohibited for veterinary use

Safety Concerns and Regulatory Background

Globally, Nimesulide has remained under scrutiny due to its hepatotoxic (liver-damaging) potential. While India still allows limited adult use, regulators have progressively restricted its scope over the years.

The ban on oral formulations above 100 mg follows a precautionary public health approach, especially since multiple safer antipyretic and analgesic alternatives are easily available in the Indian market.

Impact on the Pharmaceutical Market

Industry estimates value the Nimesulide market, including fixed-dose combinations, at around ₹500 crore. Several leading pharmaceutical companies manufacture products containing Nimesulide, including:

• Dr Reddy’s Laboratories
• Cipla
• Emcure
• Alkem

Although high-dose formulations above 100 mg had limited sales, the ban ensures complete removal of potential dosage-related risks from the legal market.

Policy Signal and Public Health Focus

Experts view the decision as a strong policy signal that patient safety will take priority over commercial considerations. Even if the affected products form a small segment, the ban ensures that no potentially harmful strength remains legally available, aligning India’s drug regulation framework with a more risk-averse public health strategy.

Exam-Oriented Key Facts

• Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID)
• India has banned oral Nimesulide formulations above 100 mg
• The ban was notified on December 31, 2025
• The drug is already banned for children below 12 years and veterinary use
• The Drugs Technical Advisory Board advises the government on drug safety

Question & Answer

Q1. Which ministry banned oral Nimesulide formulations above 100 mg?
(a) Ministry of Chemicals and Fertilizers
(b) Union Health Ministry
(c) Ministry of Consumer Affairs
(d) Ministry of AYUSH
Answer: Union Health Ministry

Q2. Nimesulide belongs to which class of drugs?
(a) Antibiotic
(b) Antiviral
(c) Nonsteroidal anti-inflammatory drug
(d) Steroid
Answer: Nonsteroidal anti-inflammatory drug

Q3. What is the main health risk associated with high-dose Nimesulide?
(a) Kidney failure
(b) Heart attack
(c) Liver toxicity
(d) Lung damage
Answer: Liver toxicity

Q4. Which body advises the government on technical matters related to drug safety?
(a) Medical Council of India
(b) CDSCO
(c) Drugs Technical Advisory Board
(d) Indian Council of Medical Research
Answer: Drugs Technical Advisory Board

Q5. Nimesulide is already banned in India for which category?
(a) Pregnant women
(b) Elderly patients
(c) Children below 12 years
(d) Diabetic patients
Answer: Children below 12 years

🔗 Other Useful Links:
📌 Latest Government Job Vacancies
📌 Latest Exam Results
📌 Free Mock Tests